SG Americas Securities LLC Increases Stake in Urogen Pharma $URGN

SG Americas Securities LLC increased its position in shares of Urogen Pharma (NASDAQ:URGN) by 19.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,377,647 shares of the company’s stock after purchasing an additional 220,264 shares during the period. SG Americas Securities LLC’s holdings in Urogen Pharma were worth $32,264,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Walleye Capital LLC purchased a new position in shares of Urogen Pharma during the second quarter valued at approximately $4,742,000. Squarepoint Ops LLC lifted its stake in shares of Urogen Pharma by 187.8% during the 2nd quarter. Squarepoint Ops LLC now owns 94,309 shares of the company’s stock worth $1,292,000 after acquiring an additional 61,545 shares during the last quarter. GSA Capital Partners LLP purchased a new position in Urogen Pharma during the 3rd quarter valued at $977,000. JPMorgan Chase & Co. grew its position in Urogen Pharma by 36.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 534,545 shares of the company’s stock valued at $10,664,000 after acquiring an additional 144,181 shares during the last quarter. Finally, NEOS Investment Management LLC purchased a new stake in Urogen Pharma in the third quarter worth $1,007,000. 91.29% of the stock is owned by hedge funds and other institutional investors.

Urogen Pharma Stock Up 2.6%

URGN opened at $18.12 on Thursday. The stock’s fifty day moving average is $19.94 and its two-hundred day moving average is $20.81. The company has a market capitalization of $882.08 million, a P/E ratio of -5.66 and a beta of 1.34. Urogen Pharma has a 52 week low of $3.42 and a 52 week high of $30.00.

Urogen Pharma (NASDAQ:URGN) last issued its earnings results on Monday, March 2nd. The company reported ($0.54) earnings per share for the quarter, topping the consensus estimate of ($0.66) by $0.12. The firm had revenue of $37.84 million during the quarter, compared to analysts’ expectations of $39.92 million. Equities analysts anticipate that Urogen Pharma will post -3.12 earnings per share for the current year.

Insider Activity

In related news, insider Mark Schoenberg sold 7,373 shares of the company’s stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $19.69, for a total value of $145,174.37. Following the completion of the sale, the insider directly owned 144,985 shares of the company’s stock, valued at $2,854,754.65. This represents a 4.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, General Counsel Jason Drew Smith sold 7,479 shares of the company’s stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $19.69, for a total transaction of $147,261.51. Following the completion of the sale, the general counsel directly owned 51,326 shares of the company’s stock, valued at approximately $1,010,608.94. This trade represents a 12.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 4.70% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on URGN shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Urogen Pharma in a research note on Wednesday, January 21st. D. Boral Capital reiterated a “buy” rating and set a $33.00 price objective on shares of Urogen Pharma in a report on Monday, March 2nd. Finally, Oppenheimer reissued an “outperform” rating on shares of Urogen Pharma in a research report on Monday, March 2nd. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Urogen Pharma currently has an average rating of “Moderate Buy” and a consensus price target of $33.29.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.